← Leaderboards
Susan L Deutscher
Harry S. Truman Memorial Va Hospital
$1,467,136
Attributed
$1,467,136
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $365.2K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,467,136 · 5
VA$0 · 1
By mechanism
R21$1,466,073 · 4
P41$1,063 · 1
I01$0 · 1
Top collaborators
- Charles J Smith3 shared
Most similar at Harry S. Truman Memorial Va Hospital
Same institution · by research overlap
- Vladislav V Glinskii$1,428,514
- Charles J Smith$96,021
Others in their field
Top investigators on “Phage Display”
- Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med$25,195,544
- Thomas William Geisbert · Boston University Medical Campus$23,202,491
- Anthony A Kossiakoff · University Of Chicago$22,138,265
- Wayne A. Marasco · Dana-Farber Cancer Inst$18,950,724
- Jeffrey W Smith · Burnham Institute For Medical Research$18,505,045
- Marc A. Shuman · University Of California San Francisco$14,093,415
Research focus
Phage DisplayLabelPeptidesTumorBacteriophagesAffinityImageMalignant NeoplasmsAntibodiesIn VivoAntigensRadiolabeledScaffoldCancer DetectionNeoplasm MetastasisBaseBreastCellsDrug KineticsKidneyDetectionCancer ImagingDiagnosisCancer Therapy
Grant awards (21)
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2025 · VA
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2024 · VA
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2023 · VA
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2022 · VA · contact PI
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2021 · VA · contact PI
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2019 · VA · contact PI
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2018 · VA · contact PI
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2017 · VA · contact PI
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents$0
I01 · FY2016 · VA · contact PI
Targeting TF/CD44v6 for In Vivo Nano-generated alpha-therapy of Ovarian Cancer$198,177
R21 · FY2015 · CA · contact PI
Multivalent Nanophage Engineered as Dual Receptor Cancer Theranostic Agents.$191,995
R21 · FY2014 · CA · contact PI
Targeting TF/CD44v6 for In Vivo Nano-generated alpha-therapy of Ovarian Cancer$166,031
R21 · FY2014 · CA · contact PI
Multivalent Nanophage Engineered as Dual Receptor Cancer Theranostic Agents.$165,962
R21 · FY2013 · CA · contact PI
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents$0
I01 · FY2013 · VA · contact PI
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents$0
I01 · FY2012 · VA · contact PI
Phage Display for Improved Peptide-based Tumor Targeting and Imaging Agents$0
I01 · FY2011 · VA · contact PI
Improved Peptide-based Tumor Targeting Agents Using Phage Display$194,355
R21 · FY2010 · CA · contact PI
Novel Ovarian Cancer Detection Agents from Phage Display$202,554
R21 · FY2009 · CA · contact PI
Improved Peptide-based Tumor Targeting Agents Using Phage Display$162,599
R21 · FY2009 · CA · contact PI
Novel Ovarian Cancer Detection Agents from Phage Display$184,400
R21 · FY2008 · CA · contact PI
Obtaining Novel Prostat-Tumor Targeting Peptides and Fab$1,063
P41 · FY2004 · RR